ArticleDiscover oncology2025
Lactylation-related gene signatures for prognosis and treatment response prediction in radiation-resistant non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lactylation Remodels Tumorigenesis, Immune Microenvironment, and Therapeutic Response.Current issues in molecular biology · 2026Review
- Unveiling lactylation: A novel frontier in the pathogenesis of diabetic nephropathy (Review).International journal of molecular medicine · 2026Review
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLactylation, as a novel type of post-translational protein modification, is closely associated with key processes such as cellular metabolism, the tumor immune microenvironment, tumor proliferation, and metastasis. However, the specific relationship between lactylation and radiation resistance in non-small cell lung cancer (NSCLC) has not yet been fully explored. This study aims to investigate the potential relationship between lactylation and radiation resistance in lung cancer using tumor databases, providing new molecular targets for individualized radiotherapy strategies for NSCLC.
methodsUsing the Cancer Genome Atlas (TCGA) database and the GSE197236 dataset on non-small cell lung cancer, the differential expression of lactate-associated radiation resistance genes (LARRGs) was analyzed. Based on the lactylation-radiation resistance model, relevant risk scores were calculated to identify high-lactylation and low-lactylation subtypes. A gene signature model based on LARRGs was developed and validated, and it was evaluated using training and validation cohorts. Additionally, immune cell infiltration and drug response were analyzed.
resultsA total of 1865 differentially expressed genes (DEGs) were identified, showing differences between radiation resistant non-small cell lung cancer (NSCLC) and normal tissues. Among these genes, 23 lactate-related differentially expressed genes (LR-DEGs) were ultimately identified through an intersection analysis of the DEGs and LARRGs. Using univariate and multivariate Cox regression analysis for further screening, three key lactate-related biomarkers were identified: RRM2B, COL4A1, and CD46. It was found that patients with high-LARRGs exhibited stronger characteristics of immune exclusion, immune exhaustion, and immunosuppression in the tumor microenvironment (TME). Additionally, in the scRNA-seq, different cell types are distinctly distributed in the reduced-dimensional space, reflecting the significant heterogeneity of the TME. Furthermore, the gene sets of fibroblasts and endothelial cells show the highest scores, suggesting that under high lactate conditions, enhanced gene expression activity in fibroblasts and endothelial cells may promote tumor radioresistance. Analysis of significantly correlated signaling pathways in the high-LARRGs indicates that metabolic reprogramming and immunosuppression may promote radioresistance through lactate-mediated inhibition of T cell function and macrophage polarization, which highlights the role of the TME in radiotherapy and suggests that targeting immune evasion mechanisms may be a key strategy to overcome radioresistance.
conclusionsLARRGs are crucial in the context of radiation resistant NSCLC, as they significantly influence tumor growth, the immune microenvironment, and drug response. This signature of LARRGs has the potential to serve as a prognostic biomarker and may also represent a promising therapeutic target for patients facing radiation resistant NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.